GlycoEra

GlycoEra is a biotechnology company that develops bifunctional biologics and extracellular protein degraders for the treatment of autoimmune diseases. The company focuses on selectively targeting and removing circulating proteins, such as autoantibodies, to treat immune-driven disorders. Their precision immunology platform aims to provide deep and selective degradation of disease-causing proteins while avoiding the broad immunosuppressive effects typical of existing therapies.